David A. Siegel Eagle Pharmaceuticals, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EGRX
# of Institutions
30Shares Held
3.82MCall Options Held
1MPut Options Held
100-
Black Rock Inc. New York, NY353KShares$412,7310.0% of portfolio
-
Ajo Vista, LLC Boston, MA56.4KShares$66,0320.92% of portfolio
-
Xtx Topco LTD London, X023.6KShares$27,6040.0% of portfolio
-
Simplex Trading, LLC18.2KShares$21,2490.0% of portfolio
-
Barclays PLC London, X014.2KShares$16,6520.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $15.2M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...